Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Schlumberger NV (SLB) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Schlumberger NVTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

Schlumberger NV vs Zimmer Biomet Holdings Inc — how do they compare? Schlumberger NV trades at $57.07 (market cap $84.74B), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B). The key difference: Schlumberger NV is far larger — about 4.7× Zimmer Biomet Holdings Inc's market cap, and Schlumberger NV pays the higher dividend (2.07%). Which is the better fit depends on your goals.

SLBZBH
Market Cap
$84.74B$17.97B
Sector
EnergyHealth
52-Week High
$60.10$104.26
52-Week Low
$31.72$79.58
Enterprise Value
$93.47B$25.04B
Dividend Yield
2.07%1.02%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Schlumberger NV

SLB trades at $57.10, down 0.71% on the day, with strong analyst support (85% buy ratings) and a $63.50 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a strategic $3.4 billion acquisition of Kelvion to expand into data center cooling technology. Revenue remains stable at $35.7 billion (2025) with solid profitability metrics including 8.53% net margin and 13.37% ROE.

The outlook remains positive with diversification into high-growth data center markets, though risks include oil price volatility and execution challenges from recent acquisitions. Current valuation at 27.85 P/E appears reasonable given growth initiatives, supporting a constructive view for long-term investors despite near-term market fluctuations.

Zimmer Biomet Holdings Inc

Zimmer Biomet (ZBH) trades at $94.22, down 3.93% on the day, with a bearish technical signal but strong fundamentals including a 69.87% gross margin and three consecutive quarterly earnings beats. Revenue growth is steady, reaching $8.23B in 2025, though net income margin dipped to 8.56%. Recent leadership promotions aim to accelerate commercial transformation, while analyst consensus price target is $104.88, implying 11.3% upside.

The stock presents a value opportunity with a P/E of 22.87 and P/S of 2.17, supported by robust cash flow and dividend payments. Risks include rising debt-to-asset ratio (32.57% in 2025) and competitive pressures. Wall Street sentiment is mixed with 40.48% buy ratings, but technical indicators suggest near-term caution amid bearish moving averages.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Schlumberger NV

Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.

Read more on SLB

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH